CRIS Stock — Curis Inc.: Cash, EV, Pipeline

Share price

$1.00

Market cap

$2.1M

Cash

$9.9M

Enterprise value

-$7.8M

Balance sheet

Cash	$9.9M
Debt	$0.0M
Net cash	$9.9M
Enterprise value	-$7.8M
Basic shares	1.9M shares
Fully diluted shares	14.7M shares
Fully diluted market cap	$14.7M
Cash per share	$5.19

Cash figures as of 2026-08-14. Database snapshot: 2026-09-21.

Price history

Loading CRIS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	Emavusertib	Phase 2	Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy; Relapsed Primary Central Nervous System Lymphoma	—
Dec 13, 2027 - Jan 24, 2028	Emavusertib	Phase 2	Chronic Lymphocytic Leukemia; B-cell Malignancies	December 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Emavusertib

Phase 2 · Active Modality: small molecule (oral)

Aliases CA-4948

Target IRAK4 and FLT3

Partnerships Aurigene Discovery Technologies: exclusive license to emavusertib (2015 collaboration)

Indications

relapsed/refractory primary CNS lymphoma (PCNSL), with ibrutinib (Phase 2)
chronic lymphocytic leukemia (frontline), with zanubrutinib (Phase 2)
acute myeloid leukemia (AML) (Stage not disclosed)

Status note TakeAim Lymphoma Phase 1/2 (CA-4948-101, +ibrutinib) in R/R PCNSL: CHMP and FDA meetings March 2025 supported a potential accelerated path (EU conditional marketing authorization / US NDA on single-arm data). TakeAim CLL Phase 2 (CA-4948-203, +zanubrutinib): dosing began July 2026. AML monotherapy/combination studies substantially complete; further AML development contingent on additional funding. Orphan Drug Designation: FDA for PCNSL/AML/MDS; EC for PCNSL. January 2026 restructuring narrowed focus to PCNSL + CLL.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Emavusertib
Lead indication	Chronic Lymphocytic Leukemia
Lead phase	Phase 2
Active trials	2
Collaborator trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07271667	Phase 2	Recruiting	Sponsor	CRIS	—	Chronic Lymphocytic Leukemia; B-cell Malignancies	December 2026
NCT03328078	Phase 2	Recruiting	Sponsor	CRIS	—	Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy; Relapsed Primary Central Nervous System Lymphoma	—
NCT05187182	Phase 1	Recruiting	Collaborator	Washington University School of Medicine	—	Gastric Cancer; Esophageal Cancer; Stomach Cancer	—
NCT07107750	Phase 1	Recruiting	Collaborator	Washington University School of Medicine	—	Metastatic Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma	—
NCT03893487	Early Phase 1	Active, not recruiting	Collaborator	Sabine Mueller, MD, PhD	—	Diffuse Intrinsic Pontine Glioma; Recurrent Anaplastic Astrocytoma; Recurrent Glioblastoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Curis, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	98,996	-1,895,941	0.15%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CRIS — Curis Inc.